This investigation consists of a longitudinal “bioactivation” phenotyping study conducted in epileptic children routinely receiving CBZ or VPA for medical management of their disease involving NICHD PPRU sites. It is anticipated that the results of this program will allow critical periods of increased bioactivation and thus, potential vulnerability to idiosyncratic ADRs, to be identified for subsequent prospective investigations.